Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study
The Journal of Clinical Hypertension, 04/25/2012Sica D et al.
In patients with stage 2 hypertension, treatment with the combination of azilsartan medoxomil (AZL–M) and chlorthalidone (CLD) resulted in substantially greater systolic blood pressure (SBP) reduction compared with either agent alone.
A total of 1714 patients with clinic systolic blood pressure (SBP) 160 mm Hg to 190 mm Hg inclusive were randomized to AZL–M 0 mg, 20 mg, 40 mg, or 80 mg and/or chlorthalidone 0 mg, 12.5 mg, or 25 mg.
The primary efficacy end point was change from baseline to 8 weeks in trough (hour 22–24) SBP by ambulatory blood pressure (BP) monitoring (ABPM).
Patients' mean age was 57 years; 47% were men and 20% were black.
Baseline trough BP was approximately 165/95 mm Hg and 151/91 mm Hg by clinic and ABPM measurements, respectively.
For the pooled AZL–M/CLD 40/25–mg and 80/25–mg FDC groups, SBP reduction by ABPM at trough was 28.9 mm Hg and exceeded AZL–M 80 mg and CLD 25 mg monotherapies by 13.8 mm Hg and 13 mm Hg, respectively (P<.001 for both comparisons).
Discontinuation rates and elevations in serum creatinine were dose–dependent and occurred more often in the AZL–M/CLD groups.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.